New Two-Drug attack on tough cancers begins human testing
NCT ID NCT07276373
Summary
This early-stage study is testing the safety and finding the right dose of a new oral drug called nenocorilant when given alongside an existing immunotherapy drug (nivolumab). It will involve about 50 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to see if the combination is safe and if it shows any early signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 01
RECRUITINGSan Antonio, Texas, 78229, United States
-
Site 02
RECRUITINGWest Valley City, Utah, 84119, United States
-
Site 03
RECRUITINGLos Angeles, California, 90025, United States
Conditions
Explore the condition pages connected to this study.